PBC: Diagnosis and Current Management Strategies
Join us live or online for a one-hour CME symposium on Diagnosis and Current Management Strategies of PBC. VIEW HERE: www.live.ddnaconference.org
Time & Location
Sep 16, 2022, 7:00 AM – 8:00 AM EDT
The W Hotel, 1439 Chestnut St, Philadelphia, PA 19102, USA
About the event
Target Audience
This activity has been designed to meet the educational needs of healthcare providers involved in the care of patients with Primary Biliary Cholangitis (PBC).
Statement of Need
The goal of this program is to provide educational updates highlighting clinically relevant advances in the management of PBC.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Define the pathophysiology, stages of progression and clinical manifestations of PBC
- Apply clinical and evidence-based diagnostic criteria to evaluate patients for PBC and emphasize the need for early surveillance
- Incorporate clinical and evidence-based treatment plans for patients with PBC effectively into practice
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and the Chronic Liver Disease Foundation (CLDF).
The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Statement
All faculty and staff involved in the planning or presentation of continuing education activities provided by the University of Cincinnati are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.
All additional planning committee members, the University of Cincinnati staff and the Chronic Liver Disease Foundation (CLDF) staff have no relationships to disclose.
Learner Assurance Statement
The University of Cincinnati is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturer(s). The University of Cincinnati is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.
Disclaimer Statement
The opinions expressed during the live activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development.
This activity is supported by an educational grant from Intercept Pharmaceuticals.